NASDAQ:FBLG FibroBiologics Q1 2025 Earnings Report $1.16 +0.03 (+2.65%) Closing price 04:00 PM EasternExtended Trading$1.14 -0.02 (-1.64%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast FibroBiologics EPS ResultsActual EPS-$2.40Consensus EPS -$2.20Beat/MissMissed by -$0.20One Year Ago EPSN/AFibroBiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFibroBiologics Announcement DetailsQuarterQ1 2025Date7/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsFibroBiologics' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) FibroBiologics Earnings HeadlinesFibroBiologics (NASDAQ:FBLG) Shares Up 5.7% - Should You Buy?May 28 at 2:37 AM | americanbankingnews.comFibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual MeetingMay 22, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 29 at 1:00 AM | Paradigm Press (Ad)FibroBiologics Files Patent Application for Oral Administration of Fibroblast TherapeuticsMay 18, 2026 | globenewswire.comFibroBiologics (FBLG) price target decreased by 28.95% to 13.77May 15, 2026 | msn.comFibroBiologics (NASDAQ:FBLG) Stock, Earnings Estimates, EPS, And RevenueMay 13, 2026 | benzinga.comSee More FibroBiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email. Email Address About FibroBiologicsFibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.View FibroBiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Shares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum BuildsMarvell’s Pullback May Be the Setup Bulls Were Waiting ForSnowflake and the Snowballing Impact of its AI FlywheelPalomar’s High-Risk Insurance Strategy Is Paying Off BigThis Quantum Computing Stock May Be Closer to a Breakout Than You Think Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
